๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase I study of MVE-2 therapy in human cancer

โœ Scribed by A. Rios; M. Rosenblum; M. Powell; E. Hersh

Publisher
Elsevier Science
Year
1982
Tongue
English
Weight
81 KB
Volume
4
Category
Article
ISSN
0192-0561

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A phase I study of recombinant human int
A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma
โœ A. Mittelman; M. Huberman; C. Puccio; B. Fallon; J. Tessitore; S. Savona; R. Eyr ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 662 KB

Preclinical data suggest synergy of interleukin-2 (IL-2) combined with alphainterferon (IFN). In addition, toxicities of IL-2 may be decreased by intermittent continuous infusion. The purpose of this trial was to determine the maximum tolerated dose (MTD) of recombinant IL-2 combined with alpha-IFN

A phase I study of interleukin-2 in chil
A phase I study of interleukin-2 in children with cancer and evaluation of clinical and immunologic status during therapy. A pediatric oncology group study
โœ Sherif Nasr; John McKolanis; Ray Pais; Harry Findley; Robert Hnath; Kathy Waldre ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 600 KB

The authors performed a Phase I study to assess the toxicity and hematologic effect of recombinant human interleukin-2 (rIL-2) in seven children with advanced malignancies. The rIL-2 was given as a bolus injection of 1 or 3 X lo6 U/m2/dose three times a week (Monday, Wednesday, and Friday) for 3 wee